Literature DB >> 24200163

Quality assessment of compounded 17-hydroxyprogesterone caproate.

Justine Chang1, Yang Zhao2, Wenchen Zhao2, Raman Venkataramanan2, Steve N Caritis1.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the quality of compounded 17-hydroxyprogesterone caproate (17-OHPC). STUDY
DESIGN: Compounded 17-OHPC that was obtained from 15 compounding pharmacies throughout the United States was analyzed for potency, impurities, sterility, and pyrogen status.
RESULTS: Eighteen samples were supplied by 15 compounding pharmacies. The concentration of 17-OHPC in all samples was within the specification limits, and all tested samples passed sterility and pyrogen testing. Only 1 of 18 samples was out of specification limits for impurities.
CONCLUSION: Compounded 17-OHPC that was obtained from 15 pharmacies throughout the United States did not raise safety concerns when assessed for potency, sterility, pyrogen status, or impurities.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  compounded 17-OHPC; impurity analysis; potency; sterility and pyrogen status

Mesh:

Substances:

Year:  2013        PMID: 24200163      PMCID: PMC3939712          DOI: 10.1016/j.ajog.2013.09.039

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate.

Authors:  Steve N Caritis; Yang Zhao; Joseph Bettinger; Raman Venkataramanan
Journal:  Am J Obstet Gynecol       Date:  2013-02-20       Impact factor: 8.661

2.  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Authors:  Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

3.  Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.

Authors:  John L Chollet; Michael J Jozwiakowski
Journal:  Drug Dev Ind Pharm       Date:  2012-02-13       Impact factor: 3.225

  3 in total
  2 in total

1.  17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.

Authors:  David B Nelson; Donald D McIntire; Jeffrey McDonald; John Gard; Paula Turrichi; Kenneth J Leveno
Journal:  Am J Obstet Gynecol       Date:  2017-02-20       Impact factor: 8.661

2.  Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.

Authors:  Amy-Eunice Furcron; Roberto Romero; Olesya Plazyo; Ronald Unkel; Yi Xu; Sonia S Hassan; Piya Chaemsaithong; Arushi Mahajan; Nardhy Gomez-Lopez
Journal:  Am J Obstet Gynecol       Date:  2015-08-08       Impact factor: 8.661

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.